Please Wait
Applying Filters...
menu
    • menu
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    Nafamostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 9,341Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    28/09/2024 Kukjeon Pharmaceutical
    South Korea
    		 Kukjeon Pharmaceutical Co., Ltd. 2520-14-ND Nafamostat mesylate 2014-08-01 Kukjeon Pharmaceutical Co., Ltd. South Korea 8, Balan Industrial Complex-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do
    28/09/2024 Kyongbo Pharmaceutical Co., Ltd
    South Korea
    		 Kyungbo Pharmaceutical Co., Ltd. 1673-41-ND Nafamostat mesylate 2021-05-25 Kyungbo Pharmaceutical Co., Ltd. South Korea 174 Silok-ro, Asan-si, Chungcheongnam-do